Equity Gap portfolio company EnteroBiotix has secured $21.5m in Series A financing to help advance its microbiome drug.
EnteroBiotix, based at Strathclyde Business Park, is developing microbial therapeutics that enhance the gut microbiome, with the new money to be used on product development and manufacturing.
The financing was led by Thairm Bio, alongside Kineticos Ventures and existing investors Scottish Enterprise and SIS Ventures.
The company plans to grow its headcount to around 50 as well as expand its analytical capabilities.
Read more HERE.